Commercialization Strategies In Oncology — The Right Partner Can Reduce Risk And Boost Rewards
By LeeAnn Steadman, Senior Vice President, Specialty Consulting, and Mike Scott, Senior Vice President, Specialty Consulting, EVERSANA
Whether you are an emerging company launching your first product or an established company expanding your portfolio, a number of parallel initiatives must be developed and executed to help your therapy get out of the shadow zone and into the limelight. Working closely with the right partner can help your company to differentiate the therapy, overcome obstacles to maximize reimbursement and patient access, and meet clinical objectives.
Manufacturers launching a new oncology therapy face numerous critical decisions including managing cost – that on average can reach $265 million over five years.
Their biggest problem is that they often do not have that breadth and depth of expertise in-house, or the physical infrastructure needed to support commercialization. Thus they often turn to third-party consultants and other experts to provide guidance.
Experts have compiled practical guidance and key factors to consider when launching a new product such as:
- Create a paradigm shift in the go-to-market strategy
- Shift the paradigm to work with a single commercialization partner
- Identify and rectify important touch points
- Clarify a therapy’s value proposition to efficiently communicate the brand story
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.